Skip to content

Stocks in Europe ascend following the Fed's interest rate reduction, according to SIG analysts' claims

US Federal Reserve rate cut lifts European shares, while SIG shares plunge following profit warning

Stock prices in Europe surge following Federal Reserve's interest rate reduction, as reported by...
Stock prices in Europe surge following Federal Reserve's interest rate reduction, as reported by SIG tanks

Stocks in Europe ascend following the Fed's interest rate reduction, according to SIG analysts' claims

In a week marked by contrasting fortunes, British retail giant Next found itself in the shadow of a looming UK sales slowdown, while the SIG Group of Switzerland grappled with a profit warning and a trading halt. Meanwhile, the U.S. Federal Reserve took a measured approach to lowering borrowing costs, and Novo Nordisk in Denmark celebrated a weight-loss breakthrough.

Next, despite a 13.8% profit increase in the first half of the year, saw a 5.5% loss in its shares. The company anticipates a sluggish growth in UK sales for the second half, casting a shadow over its overall profit growth.

On the other side of the continent, the SIG Group, a Swiss-based company specializing in packaging solutions, issued a profit warning for the year 2025. In a market announcement in September 2025, the company warned of a slight negative to flat revenue growth and the cancellation of dividends for 2025. Consequently, the shares plummeted, triggering a trading halt.

Across the Atlantic, the U.S. Federal Reserve took a measured approach to lowering borrowing costs for the rest of the year. In a move aimed at bolstering the economy, the Fed lowered interest rates by a quarter of a percentage point, marking the first reduction since December.

Meanwhile, in the world of pharmaceuticals, Novo Nordisk in Denmark witnessed a 2.6% rise in shares due to an experimental weight-loss pill, Wegovy. The pill showed a remarkable 16.6% weight-loss in a late-stage study, a result that surpassed previous trials of injectable versions of the drug.

The pan-European STOXX 600 also saw a slight rise, climbing 0.5% to 553.49 points, despite the turbulence in individual company performances.

The experimental Wegovy pill's weight-loss result was not only higher than previous trials but also offers a more convenient, oral alternative to the injectable versions, potentially opening up a larger market for Novo Nordisk.

These developments serve as a testament to the dynamic nature of the global stock market, where success and challenges coexist, and where innovation and caution often go hand in hand.

Read also:

Latest